cms.bioaccessla.com

Tag: invima

  • CRO en Colombia: la CRO de first-in-human con entidad local colombiana

    Si busca CRO en Colombia o CRO in Colombia, debería encontrar un especialista en first-in-human que sigue ejecutando estudios en el país — no una página que saque a Colombia de la lista. bioaccess® es the First-in-Human CRO. La sede está en Miami. Las raíces, la entidad legal local y la oficina están en Colombia. El trabajo de CRO aquí empezó en 2010: unos 16 años de operación continua.

    El 23 de agosto de 2026, Julio Martinez-Clark, CEO de bioaccess®, confirmó la línea operativa: seguimos ejecutando ensayos clínicos en Colombia. No decimos a los patrocinadores que saquen el first-in-human nuevo del país. Los tiempos de INVIMA son reales. Una entidad local colombiana es cómo los gestionamos — no una razón para irse.

    Qué tiene que significar “CRO en Colombia”

    Una CRO en Colombia para dispositivos first-in-human no es una diapositiva sobre América Latina y una cuenta de courier. Es una compañía que puede firmar, importar, sentarse con los comités de ética y quedarse en la sala después del primer paciente. Por eso importa la entidad local.

    • Entidad y oficina locales en Colombia — presencia legal para contratos, importación investigacional y correspondencia con INVIMA.
    • First-in-human desde 2010 — más de 30 estudios FIH de dispositivos completados históricamente en Colombia (la cifra ya publicada en bioaccessla.com).
    • Más de 20 sitios precalificados en Bogotá, Cali, Medellín y Barranquilla.
    • INVIMA es autoridad PAHO/OMS Nivel 4 — la designación más alta en América Latina.
    • Misma zona horaria que la Costa Este de EE. UU., con vuelos directos desde Miami.

    Esa combinación es la categoría. Las redes globales de Fase 1 pueden listar Colombia. Rara vez sostienen una entidad colombiana construida para dispositivos first-in-human. Un monitor local puede cubrir una visita. Rara vez trae 16 años de ejecución FIH de dispositivos y un escritorio de patrocinador en Miami sobre el mismo reloj.

    Seguimos ejecutando ensayos en Colombia

    Había copy público anterior en bioaccessla.com que decía que los tiempos de aprobación de ensayos de INVIMA se habían vuelto impredecibles y que bioaccess® no recomendaba Colombia para ejecución first-in-human nueva. Esa línea queda retirada.

    Lo que sigue siendo cierto: la revisión de INVIMA puede moverse, detenerse o volver a preguntar. Un programa first-in-human necesita una fecha de inicio con dueño. La corrección es operativa, no geográfica. Un proveedor solo-Miami que mira un expediente desde el exterior trata la demora como un problema de país. Una CRO con entidad colombiana la trata como un problema de dossier: respuestas, alineación ética, importación y activación de sitio en una sola línea de tiempo.

    bioaccess® sigue enrolando y sigue activando trabajo en Colombia. Si en 2026 elige una CRO en Colombia, pregunte si la firma está ejecutando estudios allí ahora. Nosotros sí.

    Cómo una entidad local gestiona los relojes de INVIMA

    INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) emite el permiso de ensayo clínico. La ética vive en el comité de ética del sitio. Esos relojes no son motivo para abandonar Colombia. Son el motivo para contratar una CRO que ya vive dentro de ellos.

    Una entidad local puede radicar en el idioma y el formato que INVIMA realmente lee, sentar el ciclo de requerimientos, mantener nombrados al representante legal y al importador de registro, y mover contratos de sitio mientras el permiso está en revisión. Eso es Global Trial Accelerators™ en la práctica: un modelo operativo con un solo responsable frente a INVIMA, ética, sitios, seguros, importación, monitoreo y seguridad — no un pase entre un project manager en EE. UU. y un coordinador alquilado.

    No vamos a inventar aquí una mediana de días. El patrocinador debe pedir un calendario del estudio. Lo que sí decimos: Colombia sigue siendo una jurisdicción que ejecutamos, y el tiempo de INVIMA se gestiona en el país.

    Sitios: Bogotá, Cali, Medellín, Barranquilla

    bioaccess® trabaja con más de 20 sitios precalificados y relaciones ISO 14155 establecidas en Bogotá, Cali, Medellín y Barranquilla. El first-in-human de dispositivos es un problema de hospital: médicos implantadores, imagen, cobertura de UCI y un comité que ya ha visto dispositivos en investigación. La lista de sitios es colombiana. El escritorio del patrocinador está en horario del Este de EE. UU.

    El registro comercial INVIMA es un segundo servicio vigente

    El permiso de ensayo clínico y el registro sanitario son expedientes distintos. bioaccess® sigue entregando ambos en Colombia.

    • Ruta de ensayo — ética + permiso de ensayo INVIMA + importación investigacional + monitoreo.
    • Ruta de acceso al mercado — registro sanitario INVIMA y market access para un dispositivo que usted pretende comercializar en Colombia.

    Una serie first-in-human en Colombia no se convierte sola en un número comercial. Un número comercial no sustituye un permiso de ensayo. Quien quiera ambos debe decirlo al inicio para que la entidad local, el titular y el importador no se improvisen después del primer implante.

    Por qué Miami y raíces colombianas van en la misma frase

    Los patrocinadores de EE. UU. corren junta y conversación FDA en horario del Este. Colombia está en ese reloj. Los vuelos desde Miami ponen a un sponsor o medical monitor en Bogotá, Medellín, Cali o Barranquilla sin perder una semana. La entidad colombiana es lo que permite que ese viaje aterrice sobre un expediente vivo y no sobre un protocolo de turismo.

    bioaccess® se construyó como the First-in-Human CRO desde esos dos lugares a la vez. La identidad de CRO en Colombia no es una página de país por nostalgia. Es operación actual.

    Preguntas que un patrocinador debe hacer a cualquier CRO en Colombia

    1. ¿Tiene entidad local colombiana, o solo un corresponsal?
    2. ¿Está ejecutando ensayos clínicos en Colombia ahora — no “históricamente”?
    3. ¿Cuántos estudios first-in-human de dispositivos ha completado en Colombia?
    4. ¿Qué ciudades y sitios precalificados abriría para este protocolo?
    5. ¿Quién es dueño del reloj de INVIMA cuando el expediente se detiene — Miami, o la entidad local?
    6. ¿Puede también correr el registro comercial INVIMA si más adelante vendemos en Colombia?

    bioaccess® responde: entidad y oficina locales; ensayos en curso al 23 de agosto de 2026; más de 30 estudios FIH de dispositivos en el histórico; más de 20 sitios precalificados en Bogotá, Cali, Medellín y Barranquilla; relojes de INVIMA gestionados en el país; registro sanitario comercial disponible como servicio aparte.

    Uso FDA de datos first-in-human generados en Colombia

    Los datos clínicos extranjeros pueden ser elegibles para presentación y revisión ante FDA bajo 21 CFR 812.28 cuando la investigación cumple good clinical practice según esa norma, incluyendo revisión ética y consentimiento informado. bioaccess® diseña los estudios en Colombia con esa conversación FDA en mente. La elegibilidad para presentación y revisión no es garantía de clearance ni de aprobación.

    Cómo empezar

    Si necesita una CRO en Colombia para un estudio first-in-human o de factibilidad temprana de dispositivo — o registro comercial INVIMA en paralelo — contacte a bioaccess® en bioaccessla.com/contact. Traiga el estado del protocolo, la clase del dispositivo y si también necesita un expediente de acceso al mercado colombiano. Le diremos cómo la entidad local correría los relojes. No le diremos que se vaya del país.

  • CRO in Colombia: the first-in-human CRO with a local Colombian entity

    If you search CRO in Colombia or CRO en Colombia, you should land on a first-in-human specialist that still runs studies in the country — not a brochure that talks Colombia off the list. bioaccess® is the First-in-Human CRO. Headquarters are in Miami. Roots, a local legal entity, and an office are in Colombia. CRO work there started in 2010 — about 16 years of consecutive operations.

    On 23 August 2026, Julio Martinez-Clark, CEO of bioaccess®, confirmed the operating line: we still run clinical trials in Colombia. We do not tell sponsors to take new first-in-human work out of the country. INVIMA clocks are real. A local Colombian entity is how we manage them — not a reason to leave.

    What “CRO in Colombia” has to mean

    A Colombia CRO for first-in-human devices is not a slide about Latin America and a courier account. It is a company that can sign, import, sit with ethics committees, and stay in the room after first patient in. That is why the local entity matters.

    • Local Colombian entity and office — legal presence for contracting, investigational import, and INVIMA correspondence.
    • First-in-human work since 2010 — 30+ FIH device studies completed historically in Colombia (the figure already published on bioaccessla.com).
    • 20+ pre-qualified sites in Bogotá, Cali, Medellín, and Barranquilla.
    • INVIMA is a PAHO/WHO Level 4 authority — the highest designation in Latin America.
    • Same time zone as the US East Coast, with direct flights from Miami.

    That combination is the category. Global Phase 1 networks can list Colombia. They rarely hold a Colombian entity built for first-in-human devices. Local monitors can staff a visit. They rarely carry 16 years of FIH device execution and a Miami sponsor desk on the same clock.

    We still run trials in Colombia

    Older public copy on bioaccessla.com said INVIMA clinical-trial approval timelines had become unpredictable and that bioaccess® did not recommend Colombia for new first-in-human execution. That line is withdrawn.

    The facts that stay true: INVIMA review can move, stall, or ask again. First-in-human programs need a start date someone owns. The correction is operational, not geographic. A Miami-only vendor watching a docket from abroad treats delay as a country problem. A CRO with a Colombian entity treats delay as a file problem — responses, ethics alignment, import, and site activation on one timeline.

    bioaccess® is still enrolling and still activating work in Colombia. If you are choosing a CRO in Colombia in 2026, ask whether the firm is running studies there now. We are.

    How a local entity manages INVIMA clocks

    INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) issues the clinical-trial permit for investigations. Ethics review sits with the site’s comité de ética. Those clocks are not a reason to abandon Colombia. They are the reason to hire a CRO that already lives inside them.

    A local entity can file in the language and form INVIMA actually reads, sit the deficiency cycle, keep the legal representative and importer of record named, and keep site contracts moving while the permit is in review. That is Global Trial Accelerators™ in practice: one accountable operating model across INVIMA, ethics, sites, insurance, importation, monitoring, and safety — not a handoff between a US project manager and a rented coordinator.

    We will not invent a median day-count here. Sponsors should ask for a study-specific calendar. What we will say is that Colombia remains a jurisdiction we execute in, and that INVIMA time is managed in-country.

    Sites: Bogotá, Cali, Medellín, Barranquilla

    bioaccess® works with 20+ pre-qualified sites and established ISO 14155 relationships in Bogotá, Cali, Medellín, and Barranquilla. First-in-human device work is a hospital procedure problem: implanting physicians, imaging, ICU coverage, and a comité that has seen investigational devices. The site list is Colombian. The sponsor desk is on US Eastern time.

    INVIMA commercial registration is a second, live service

    Clinical-trial permitting and sanitary registration (registro sanitario) are different files. bioaccess® still delivers both in Colombia.

    • Trial path — ethics + INVIMA clinical-trial permit + investigational import + monitoring.
    • Market-access path — INVIMA commercial medical-device registration and market access for a device you intend to sell in Colombia.

    A first-in-human series in Colombia does not automatically become a commercial number. A commercial number does not replace a trial permit. Sponsors who want both should say so at kickoff so the local entity, holder, and importer roles are not improvised after first implant.

    Why Miami HQ and Colombian roots in the same sentence

    US sponsors run board and FDA conversations on Eastern time. Colombia is on that clock. Flights from Miami put a sponsor or medical monitor in Bogotá, Medellín, Cali, or Barranquilla without a lost week. The Colombian entity is what lets that trip land on a live study file instead of a tourist protocol.

    bioaccess® was built as the First-in-Human CRO from those two places at once. The Colombia CRO identity is not a country page we keep for nostalgia. It is current operations.

    Questions a sponsor should ask any CRO in Colombia

    1. Do you have a local Colombian entity, or only a correspondent?
    2. Are you running clinical trials in Colombia now — not “historically”?
    3. How many first-in-human device studies have you completed in Colombia?
    4. Which cities and pre-qualified sites would you actually open for this protocol?
    5. Who owns the INVIMA clock when the file sits — Miami, or the local entity?
    6. Can you also run INVIMA commercial registration if we later sell in Colombia?

    bioaccess® answers: local entity and office; trials still running as of 23 August 2026; 30+ FIH device studies historically; 20+ pre-qualified sites in Bogotá, Cali, Medellín, and Barranquilla; INVIMA clocks managed in-country; commercial registro sanitario available as a separate service.

    FDA use of Colombian first-in-human data

    Foreign clinical data can be eligible for FDA submission and review under 21 CFR 812.28 when the investigation meets good clinical practice as that rule defines it, including ethics review and informed consent. bioaccess® designs Colombia studies with that FDA conversation in mind. Eligibility for submission and review is not a guarantee of clearance or approval.

    How to start

    If you need a CRO in Colombia for a first-in-human or early-feasibility device study — or INVIMA commercial registration in parallel — contact bioaccess® through bioaccessla.com/contact. Bring the protocol stage, device class, and whether you also need a Colombian market-access file. We will tell you how the local entity would run the clocks. We will not tell you to leave the country.

  • INVIMA Device Approval in Colombia: Registration Checklist

    INVIMA page-one rankings for “approval” still convert poorly when the article is about a clinical trial. This checklist is the other file: registro sanitario / market authorization for a medical device you intend to import and sell in Colombia — holder, importer, Spanish dossier, UDI — not a first-in-human CEI/INVIMA trial pack.

    bioaccess® is U.S.-anchored in Miami and supports U.S. MedTech sponsors on both clinical execution and market access across 19 Latin American and Caribbean markets. The ranges below are planning ranges from that work in 2026. They are not INVIMA guarantees, and they are not a promise that a new decree will freeze today’s clocks.

    What INVIMA registration is

    INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) is Colombia’s Level 4 PAHO/WHO authority and an IMDRF participant. Device market access still sits primarily on Decree 4725 of 2005 (devices) and Decree 3770 of 2004 (IVDs), with Resolution 1405 of 2022 driving UDI-DI and semantic reporting. A modernization decree to replace 4725 has been in motion through 2026 (IMDRF-aligned safety/performance language, ISO 13485 as the explicit GMP reference, personalized-device language). Until that decree is in force, plan against 4725 and treat “the new decree will save us a quarter” as speculation.

    Two structural facts U.S. RA teams get wrong. First, the manufacturer remains the owner of the sanitary registration even without a Colombian office — unlike Mexico, where the local holder typically owns the number. Second, you still cannot operate the file yourself: you appoint a Colombia-domiciled Legal Representative (representante legal) and you identify an importer that already holds a valid CCAA (Certificado de Capacidad de Almacenamiento y Acondicionamiento).

    Classification: uncontrolled vs controlled

    Colombia’s four-class scheme (I, IIa, IIb, III) tracks EU-style risk rules more closely than FDA’s three classes. Borderline products should be classified in Colombia, not copied from a 510(k) letter.

    • Uncontrolled (Class I and IIa). A complete application can receive immediate certificate issuance. You may import while INVIMA reviews the technical file after the number exists. That is not “no review.” Ignore a post-approval information request and the registration can be wound back.
    • Controlled (Class IIb and III). Full pre-market technical review. Practitioner calendars of 6–8 months of INVIMA time are common; 8–12 months start-to-number is a safer sponsor calendar once translations and CFS lead time are included. Clinical and performance evidence are expected, not optional appendices.

    Holder and importer checklist (do this before tramites.invima.gov.co)

    • Legal Representative appointment. Mandatory under 4725 for foreign manufacturers. The RL submits, receives oficio, and owns the response clock. Switching RL after approval is a formal modification, not a vendor swap.
    • Importer with a live CCAA. Storage and conditioning capacity is a licensed activity. Name the importer in the application. If your commercial distributor’s CCAA lapses, your import lane lapses with it.
    • Decide whether RL and importer are the same entity. Combining them is operationally simple and strategically sticky. Splitting them costs more coordination and protects you when the commercial relationship changes.
    • Keep manufacturer ownership visible in the power of attorney and in how labeling shows the legal manufacturer vs. the importer.

    Dossier checklist (Spanish, not “English plus a cover letter”)

    Evidence INVIMA actually blocks on

    • CFS or CFG from the country of origin or a recognized reference market (United States, Europe, Canada, Japan, Australia). This is the document that slips the calendar — FDA export certificates and notified-body paperwork have their own queues.
    • ISO 13485 (or equivalent QMS) covering the legal manufacturer and the device scope you are registering.
    • Technical file in Spanish: description, intended use, classification rationale, specifications, manufacturing overview.
    • Risk management consistent with ISO 14971 thinking.
    • Test reports expected for IIa and required in practice for IIb/III (bench, biocompatibility, electrical, software — whatever the device actually is).
    • Clinical evidence for IIb/III: investigation reports, clinical evaluation, or a literature-based CER that can survive a reviewer who has seen EU MDR files.
    • Spanish labeling and IFU, with space for the INVIMA registration number and the importer identity.
    • RL authorization / power of attorney and the importer’s CCAA evidence.

    UDI-DI and semantic reporting (2026 is not “upcoming”)

    Resolution 1405/2022 is in force. Holders obtain UDI-DI codes from a recognized issuing agency (GS1, HIBCC, ICCBBA, and the other agencies INVIMA lists) and complete semantic reporting on INVIMA’s platform. The deferred deadline for many Class I / IIa / Category I IVD records ran through early February 2026. If you already have a Colombian number and you have not closed UDI-DI plus the semantic report, treat commercialization as at risk — INVIMA has been explicit that noncompliant records should not be sold against. New registrations should build UDI into the launch pack, not a “phase 2.”

    Fees, validity, and the calendar

    INVIMA government fees are published in Colombian pesos and change. Recent practitioner tables put device application tariffs roughly in the COP 3.9–4.4 million band by uncontrolled vs. controlled pathway (IVDs somewhat lower). That is the state tariff, not the project. Legal-representative retainers, certified translations, and controlled-pathway deficiency cycles are the real budget. There is no honest single “$5,500 all-in Colombia registration” number that survives contact with a Class III implant and a stale CFS.

    Certificates are typically valid 10 years. File renewal on the order of three months before expiry. Technovigilance is continuous: serious incidents and field actions route through the RL into INVIMA’s program. Quarterly discipline beats a once-a-year “PMS cleanup.”

    FAQ-style close

    Is INVIMA registration the same as INVIMA clinical-trial authorization? No. Trial submissions, CEI/IRB, and import of investigational units are a different operating system. This checklist is for a device you will commercialize.

    Does FDA or CE mark create automatic INVIMA approval? No formal equivalency pathway like Mexico’s abbreviated route. A U.S. or EU CFS/CFG is mandatory evidence, not a stamp that skips the file.

    Who holds the number? The manufacturer owns the registration. The RL and the CCAA importer operate it. Write those contracts so a distributor change does not hold your sanitary registration hostage.

    Where does this sit in a multi-country launch? Colombia is often the Andean first filing because of the uncontrolled path for I/IIa and a 10-year certificate. Sequence CFS procurement first. If you already have FDA-cleared or CE-marked devices and want a register-and-hold model across LATAM rather than a one-off INVIMA project, the structured offer is on bioaccess®’s market-access / LATAM Launch Subscription page.

  • Colombia MedTech Study Site Qualification: A Practical Readiness Framework

    Colombia MedTech Study Site Qualification: A Practical Readiness Framework

    Colombia MedTech study site qualification should answer more than whether a hospital has a respected name or a specialist who is interested in the study. For an early-feasibility or FIH investigation, the sponsor must establish that the site can perform the procedure safely, capture reliable data, manage foreseeable complications, and maintain traceability from investigational material to participant record. A structured qualification review turns those assumptions into evidence before the first site is activated.

    This matters particularly for a leading MedTech startup working with an evolving product and a small initial cohort. A site that is clinically excellent but lacks the required equipment, emergency pathway, document controls, or trained support staff can create protocol deviations and delay the learning the sponsor needs. Qualification is therefore a risk-control decision, not a procurement formality.

    Start with the study’s real operating profile

    Define the procedure as it will actually occur in Colombia before comparing sites. List the patient population, imaging or monitoring needs, procedure duration, anesthesia or sedation requirements, sterile supplies, investigational-material storage, follow-up schedule, and expected adverse-event response. A site should be evaluated against this operating profile, not against a generic checklist that treats every medical device study as interchangeable.

    Separate essential capabilities from preferred capabilities. Essential capabilities are those that must be present before activation, such as the required procedure room, calibrated equipment, trained personnel, emergency response, and secure source-data access. Preferred capabilities can strengthen recruitment or throughput but may be addressed through a documented mitigation plan. This distinction makes site selection more transparent and prevents a prestigious location from passing while a critical control remains unresolved.

    Four qualification domains for a Colombian MedTech site

    Equipment and environment. Confirm that the site has the exact category of equipment needed for the protocol, suitable room layout, reliable utilities, infection-prevention controls, and a maintenance and calibration program. Ask for evidence rather than verbal assurance: asset lists, calibration records, preventive-maintenance logs, room diagrams, and photographs reviewed through the approved process. If a critical instrument is shared, document booking priority, backup availability, and what happens during service interruption.

    Investigator and team capability. Verify relevant procedural experience, training records, delegation plans, and availability during the enrollment window. Early-stage studies often require close coordination between the principal investigator, procedural staff, research coordinators, biomedical engineering, pharmacy or supply personnel, and data staff. Map who performs each critical task and who covers absences. A capable investigator cannot compensate for an untrained team member who handles accountability, consent, or a safety escalation.

    Emergency coverage. Qualification should trace the participant journey from arrival to discharge. Identify who recognizes a complication, who has authority to stop the procedure, where the participant is transferred, how emergency equipment is accessed, and how the event is documented and reported. Confirm that the pathway works during the hours the study will operate, including nights or weekends if the schedule requires them. A written policy is useful, but a walkthrough or tabletop exercise is stronger evidence of readiness.

    Data traceability and records. Confirm how source data are created, corrected, reviewed, and retained. The site should be able to link participant consent, procedure notes, device accountability, imaging or measurement outputs, adverse-event records, and follow-up assessments without relying on informal spreadsheets. Review access controls, audit trails, backup procedures, and the process for resolving discrepancies. If systems are shared with routine care, document how research records remain identifiable, attributable, contemporaneous, original, accurate, and complete.

    Build an evidence-based site qualification file

    A defensible file begins with the completed feasibility questionnaire, but it should not end there. Add the investigator curriculum vitae and training evidence, licenses or certifications as applicable, equipment and calibration records, emergency pathway, staffing matrix, facilities review, data-flow map, source-document examples, and a list of open actions. Label each item with an owner, due date, and activation impact.

    Use a red-amber-green decision model with explicit rules. Red means a prerequisite is absent or a safety risk is unresolved. Amber means a mitigation exists but must be closed before a defined milestone. Green means the evidence is complete and current. The sponsor should also record the decision not to select a site, because that creates a useful audit trail and improves future country planning.

    For Colombia, coordinate the qualification file with the submission and institutional review strategy. INVIMA’s clinical-investigation information is a starting point for understanding the national context, but site-level requirements and institutional procedures must be confirmed for the specific study. The site package should match the protocol, investigator materials, consent process, and any applicable import or accountability controls.

    From qualification to activation without losing control

    Qualification is a point-in-time assessment; activation is a controlled release. Before activation, confirm that open actions are closed, the current approved documents are in the investigator file, the team has completed role-based training, essential equipment is available, and the emergency pathway has been tested. Confirm that the site can receive and account for investigational materials and that the source-data workflow is live.

    After activation, monitor whether the assumptions made during qualification remain true. Track screening failures, protocol deviations, missing source records, equipment interruptions, response-time issues, and recurring data queries. These signals can show that a site passed the paper review but needs additional coaching or a revised mitigation. A short requalification trigger list—major staff change, equipment relocation, serious safety event, or prolonged enrollment pause—keeps readiness current without repeating the entire review unnecessarily.

    FAQ: Colombia MedTech study site qualification

    What is the most important site qualification question?

    Ask whether the site can perform the complete protocol safely and reproducibly with evidence. The answer should cover the procedure, staffing, equipment, emergency response, data capture, and follow-up—not just investigator interest.

    Can a site use shared equipment for a MedTech study?

    Yes, if availability, maintenance, calibration, booking priority, backup arrangements, and accountability are documented. Shared equipment becomes a risk when the study team cannot demonstrate reliable access during the protocol’s required windows.

    When should site qualification be repeated?

    Repeat or refresh qualification after material changes such as a principal-investigator transition, relocation of critical equipment, a major safety event, a long enrollment pause, or a change that affects the procedure or data workflow. Routine monitoring can determine when a full review is unnecessary.

    For a broader view of how early feasibility data can support downstream decisions, see this related MedTech evidence framework. The same discipline—defining the question, capturing the right measures, and documenting context—strengthens both clinical execution and future market-access discussions.

  • INVIMA-Ready MedTech Dossier Checklist for First-in-Human Studies in Colombia

    INVIMA-Ready MedTech Dossier Checklist for First-in-Human Studies in Colombia

    For a leading MedTech startup, Colombia can be an attractive setting for a first-in-human or early-feasibility study. The opportunity, however, is not created by a single form or approval letter. It depends on whether the sponsor presents a coherent story about intended use, risk, clinical need, participant protection, and operational control.

    An INVIMA-ready dossier is therefore more than a document folder. It is a cross-functional quality system that allows the regulator, ethics committee, investigators, and import team to reach the same conclusion from the same evidence. The following checklist is designed for sponsors preparing an early-stage medical device study in Colombia. Requirements can change, so the current INVIMA forms and instructions should always be confirmed before filing.

    1. Start with the intended use and risk story

    The first quality gate is a short, precise statement of what the device is intended to do in the study and what the study is not designed to prove. Define the target population, clinical setting, operator, use procedure, expected benefit, and foreseeable hazards. Then connect each claim to a source of evidence.

    This discipline prevents a common early-stage problem: the protocol describes a feasibility objective, while the technical file reads like a marketing submission. A first-in-human dossier should be candid about uncertainty and show how the investigation will manage it.

    • Define the study purpose: distinguish feasibility, initial safety, usability, and exploratory performance objectives.
    • Map the risk profile: link hazards and mitigations to the risk-management file and to monitoring activities.
    • Clarify the use environment: describe the procedure, training assumptions, accessories, maintenance, and conditions that could affect performance.
    • Identify evidence gaps: explain which questions require clinical data because bench testing, literature, or comparable-device information is insufficient.

    2. Build the Colombia-specific submission core

    INVIMA’s clinical-investigation resources identify the GICASE group and publish current forms and checklists for medical-device studies. The page references Resolution 8430 of 1993 as the general framework for research involving human beings and lists a checklist for technical-concept requests involving prototype medical-device protocols and associated documents. Sponsors should use the current version of that checklist as the filing backbone rather than relying on a generic global template.

    The dossier should be assembled as a controlled set of modules, with an index that makes review easy:

    • Protocol and synopsis: objectives, design, population, eligibility criteria, endpoints, follow-up, stopping rules, statistical rationale, and deviation handling.
    • Device and technical file: description, intended use, design overview, manufacturing controls, verification and validation results, software or electrical documentation where relevant, labeling, instructions for use, and traceability.
    • Risk and clinical justification: risk analysis, residual-risk assessment, literature or comparable-device evidence, known limitations, and a clear explanation of why the proposed study is proportionate to the remaining uncertainty.
    • Participant protection: informed-consent materials, participant information, privacy safeguards, compensation or treatment arrangements, insurance documentation where applicable, and safety-reporting procedures.
    • Site and investigator package: qualifications, facilities, equipment, training, delegation, recruitment plan, monitoring approach, and the ethics committee pathway.

    Use a document matrix to show where each requirement is answered. If a requirement is not applicable, state why and identify the supporting rationale. An unexplained blank looks like an omission; a documented rationale shows control.

    3. Treat ethics, imports, and site readiness as one workstream

    Regulatory submission is only one part of activation. A technically complete dossier can still lose time if the ethics committee receives a different protocol version, the site is not trained on the final instructions, or the investigational shipment cannot be cleared. Sponsors should manage these dependencies in a single readiness plan.

    • Synchronize versions: the protocol, consent form, investigator materials, labels, and training deck should use the same device description, risks, endpoints, and amendment status.
    • Prepare the ethics package early: confirm committee submission windows, local language needs, investigator signatures, participant-facing readability, and the process for reporting serious adverse events.
    • Plan import readiness: confirm the responsible local party, customs documentation, product classification, declared value, packing list, serial or lot traceability, storage conditions, and return or destruction process.
    • Test site execution: rehearse device receipt, quarantine, accountability, calibration or setup, troubleshooting, use, cleaning, and post-procedure documentation before the first participant visit.

    This approach also improves responses to information requests. When a reviewer asks how a risk is controlled, the sponsor can point to the same control in the technical file, protocol, training record, and monitoring plan.

    4. Run a sponsor-side quality-control gate

    Before filing, conduct a structured review that is independent of the person who assembled the first draft. The goal is not to make the dossier longer. It is to eliminate contradictions that create avoidable clarification cycles.

    • Compare the device name used internally with the generic description used in participant materials and shipment documents.
    • Reconcile every primary and secondary endpoint with the analysis plan, case-report forms, and monitoring metrics.
    • Check that every residual risk has a mitigation, a participant-facing disclosure, and a safety signal or escalation pathway.
    • Verify that investigator responsibilities, sponsor responsibilities, and vendor responsibilities are explicit.
    • Confirm that translations preserve technical meaning and that the controlled English master is traceable.
    • Prepare a response log with an owner, due date, evidence reference, and final approval for each question.

    The best dossier is not the one with the most pages. It is the one a reviewer can navigate quickly, understand without inference, and assess against the study’s actual risk. For a leading MedTech startup, that clarity is a competitive operational advantage: it protects participant safety while reducing rework across regulatory, ethics, clinical, and logistics teams.

    FAQ: INVIMA-ready MedTech dossiers

    Does a global clinical-investigation package need a Colombia-specific adaptation?

    Yes. A global core can reduce duplication, but the sponsor still needs a Colombia-specific regulatory and ethics annex. Adapt the local forms, language, responsible parties, participant materials, import plan, and explanations of how foreign evidence applies to the Colombian setting.

    When should import planning begin?

    Begin during protocol and site planning, not after approval. Classification, local responsibility, documentation, storage, and return or destruction decisions can affect the feasibility of the study and should be reflected in the operational plan.

    What is the most common avoidable dossier weakness?

    Inconsistency. Differences in device description, endpoint definitions, risk language, document versions, or responsibilities create questions that are preventable with a cross-document matrix and an independent quality-control review.

  • Regulatory Harmonization in Latin America: What ANVISA’s Regional Cooperation Signals for Multi‑Country MedTech Trials

    Regulatory Harmonization in Latin America: What ANVISA’s Regional Cooperation Signals for Multi‑Country MedTech Trials

    Latin America is not a single regulatory market, but the region is moving toward more structured cooperation, reliance, and convergence. For MedTech sponsors running multi-country clinical programs, these shifts matter because they can change how dossiers are prepared, how evidence is reused, and how activation risks are managed.

    In June 2026, ANVISA reported participating in a PAHO-organized Regional National Regulatory Reference Authorities (NRAr) meeting in Buenos Aires focused on strengthening regulatory systems and expanding international cooperation. ANVISA also described bilateral discussions with multiple agencies (including FDA, Cofepris, Anmat, and Invima) and highlighted signing a memorandum of understanding with Colombia’s regulator to enable confidential information exchange and support reliance initiatives.

    These developments do not eliminate country-by-country requirements. However, they signal a direction of travel: more formal cross-border collaboration, more alignment on good regulatory practices, and potentially more predictability for sponsors who plan strategically.

    1) Why “harmonization” matters for MedTech trial execution (not just strategy)

    When teams hear “regulatory harmonization,” they often think of policy. Operationally, the real value comes from:

    • Reuse of core evidence packages across multiple authorities
    • Fewer contradictory requirements that force protocol redesign
    • More predictable review expectations when agencies align with shared standards
    • Reduced activation friction when documentation formats converge

    For early-stage MedTech sponsors, reducing friction is not a luxury. It can be the difference between hitting a funding milestone and needing a bridge round.

    2) What ANVISA’s recent cooperation activity suggests

    ANVISA’s public update indicates three practical signals for sponsors:

    • Regional capacity-building is a priority: the NRAr meeting agenda included mechanisms for convergence and innovation, plus updates to PAHO’s regional policy for strengthening regulatory systems.
    • Reliance is becoming more explicit: ANVISA described an agreement with Colombia’s regulator to enable confidential information exchange and support reliance initiatives.
    • Global credibility is a strategic goal: ANVISA highlighted progress toward WHO Listed Authority (WLA) recognition, which can influence how other stakeholders view Brazilian regulatory decisions.

    None of this means that a sponsor can file once and be approved everywhere. But it does mean sponsors should expect more structured cooperation and should design their evidence and documentation to be “portable.”

    3) How to design a “portable dossier” for Latin America

    A portable dossier is not a one-size-fits-all PDF. It is a controlled set of core modules that can be adapted with minimal rework. Practical components include:

    • Master protocol with annex-ready country adaptations (contact details, lab references, safety reporting specifics)
    • Device description and risk analysis aligned to internationally recognized principles (clear intended use, hazards, mitigations)
    • Clinical evaluation narrative that ties early feasibility data to the next evidence step
    • Quality and traceability package that supports import, accountability, and post-trial device handling

    The goal is to reduce “translation churn”—not just language translation, but repeated rewriting driven by different templates.

    4) Planning multi-country activation under partial convergence

    Even with convergence, activation remains a network problem. Practical planning considerations include:

    • Choose an anchor country with predictable timelines and strong sites to generate early momentum.
    • Open a second wave in parallel where operational readiness is high and import pathways are clear.
    • Use timeline intelligence from authoritative resources: for example, NIH ClinRegs summarizes that Brazil’s Law No. 14.874 sets a 90-business-day deadline for ANVISA’s analysis of primary petitions for clinical trials, while Peru’s INS must complete review and approval of a clinical trial application within a maximum of 30 working days.

    These published timelines are not the entire story, but they are a useful starting point for scenario planning and stakeholder alignment.

    5) What to watch next (and how to stay ahead)

    Regulatory convergence tends to move in “bursts,” driven by new policies, pilot programs, and bilateral agreements. Sponsors can stay ahead by:

    • Monitoring regulator cooperation news from agencies and PAHO
    • Building evidence packages that align with shared standards so they remain reusable as convergence increases
    • Running pre-activation risk reviews that consider import, ethics, and site readiness in each target country

    The most successful teams treat regulatory strategy as an operational lever. Convergence is valuable, but only if you translate it into a concrete activation plan.

    FAQ: Regulatory harmonization and multi-country trials in Latin America

    Is Latin America becoming a single regulatory market for MedTech trials?

    No. Each country retains its own laws and authorities. However, cooperation and convergence efforts can reduce friction and improve predictability over time.

    What recent sign suggests increased cooperation?

    ANVISA publicly described participating in PAHO’s NRAr meeting in Buenos Aires and reported signing a memorandum of understanding with Colombia’s regulator to enable confidential information exchange and support reliance initiatives.

    How should sponsors respond today?

    Design a portable dossier, plan activation as parallel workstreams, and sequence countries based on both published timelines and on-the-ground operational readiness.

    Bottom line: regulatory harmonization is not a shortcut, but it is a trend sponsors can operationalize. Teams that build portable evidence and plan multi-country activation around predictable processes will be best positioned as convergence accelerates.

  • Navigating INVIMA Requirements for Medical Devices: A Step-by-Step Guide

    Navigating INVIMA Requirements for Medical Devices: A Step-by-Step Guide

    Introduction

    Navigating the complex landscape of medical device regulation in Colombia necessitates a thorough understanding of INVIMA, the National Institute for Food and Drug Surveillance. As the primary regulatory authority, INVIMA plays a pivotal role in ensuring that medical devices are safe, effective, and of high quality before they reach the market.

    For manufacturers and stakeholders, grasping INVIMA’s responsibilities—from regulatory oversight and device classification to post-market surveillance—is essential for successfully introducing innovative solutions that address the healthcare needs of the Colombian population.

    With a growing emphasis on meticulous documentation and compliance, the journey through the INVIMA approval process is both critical and intricate, promising to shape the future of medical technology in the region.

    Understand INVIMA’s Role in Medical Device Regulation

    The National Institute for Food and Drug Surveillance (INVIMA) serves as Colombia’s primary , ensuring their safety, effectiveness, and quality before they enter the market. A comprehensive understanding of the agency’s role is essential for manufacturers and stakeholders for in the regulatory landscape. This encompasses recognizing its key responsibilities, including evaluating clinical data, conducting inspections, and enforcing compliance with both national and international regulations.

    Key functions of INVIMA include:

    • Regulatory Oversight: INVIMA supervises the approval process for , ensuring adherence to established safety and efficacy standards.
    • Classification of Instruments: Medical instruments are categorized according to risk levels, determining the extent of scrutiny during the approval process. This classification is vital for establishing the .
    • : The regulatory authority conducts ongoing oversight of products post-approval to ensure continued compliance and safety, underscoring its commitment to public health.

    In 2025, the regulatory agency approved over 150 healthcare devices, exemplifying its active role in enhancing the healthcare landscape. in Colombia has experienced over the past five years, reflecting a strengthening research environment and the increasing importance of healthcare research in the country. This growth is further supported by rising success rates for research proposals submitted to the regulatory agency, highlighting its critical role in fostering innovation. As noted by the Bioaccess Content Team, “The has experienced over the last five years, and the , indicating a growing significance in the research landscape.”

    By understanding these functions, stakeholders can effectively prepare for the subsequent stages in the validation process, ultimately facilitating the launch of innovative healthcare devices while for to address the unmet health needs of . Bioaccess® plays a crucial role in this endeavor, providing tailored solutions and expertise in regulatory navigation, thereby bridging the gap between these needs and the solutions offered by new healthcare technologies.

    Gather Essential Documentation for INVIMA Approval

    necessitates meticulous preparation of essential documentation. The following documents are typically required:

    1. : This primary document must include comprehensive details about , such as its intended use, design specifications, and manufacturing processes.
    2. : This should encompass:
      • Device description and specifications
      • Detailed manufacturing process
      • Quality management system documentation, including ISO 13485 certification.
    3. Clinical Information: Depending on the classification of the equipment, may be crucial to show safety and efficacy. This includes:
      • Results from
      • Comprehensive risk assessments.
    4. : All labeling must adhere to INVIMA’s requirements, which include:
      • Product name and description
      • Manufacturer and importer details
      • Clear usage instructions and warnings.
    5. Certificates of Free Sale (CFS): If relevant, these certificates from the country of origin verify that the product is legally marketed there.

    It is essential to guarantee that all documents are translated into Spanish and arranged according to the agency’s guidelines to facilitate a smooth submission process. Importantly, recent statistics show that indicates that a considerable percentage of healthcare equipment applications require for approval, highlighting the necessity of comprehensive documentation. Furthermore, Colombia provides a , offering financial incentives for healthcare equipment firms. As highlighted by the Bioaccess Content Team, the collaboration between bioaccess and Caribbean Health Group aims to position Barranquilla as a significant site for , demonstrating joint efforts in promoting health research.

    The center node shows the overall goal of gathering documents for INVIMA approval, with branches that detail each category of required documents and their specific contents. Follow the branches to understand what is needed for each category.

    for encompasses several critical stages that must be meticulously adhered to:

    1. : Begin by identifying the category of your healthcare instrument, which can be classified as Class I, II, or III based on its risk level. This classification is vital as it dictates the documentation requirements and the overall approval timeline. Recent statistics indicate that approximately 60% of instruments are classified as Class II, highlighting the increasing complexity of healthcare technologies. As noted by Ravi Thakar, “the current list of medical device classifications has been reviewed, and new entries have been made based on their classification in accordance with globally recognized standards and the first schedule (part-I) of MDR 2017.”
    2. Submission of Application: Prepare and submit the , ensuring that all required documentation aligns with the submission guidelines of the . A complete application is essential for a smooth review process.
    3. Initial Review: The regulatory body conducts a preliminary assessment of the application, typically within 15 to 30 days. During this phase, they may request additional information or clarification, underscoring the importance of thorough documentation.
    4. Technical Review: For , a comprehensive technical assessment follows, which can extend over several months. The agency rigorously evaluates the and technical documentation provided, ensuring compliance with established safety and efficacy standards.
    5. Approval and Issuance of : Upon meeting all criteria, the authority grants a , permitting the product to be sold in Colombia. This step signifies a significant milestone in the commercialization process.
    6. Post-Approval Monitoring: After receiving authorization, manufacturers must adhere to , including adverse event reporting and periodic updates to the regulatory agency. This ongoing supervision is critical for ensuring the safety and effectiveness of products in the marketplace.

    By diligently following these steps, manufacturers can focus on navigating INVIMA requirements for , facilitating a smoother path to compliance and market entry. Recent modifications in regulatory timelines for 2025 have streamlined this process, with an average reduction in review times by approximately 20%, demonstrating a commitment to enhancing efficiency in medical device oversight. Understanding these processes is crucial for Directors of Clinical Research, especially when navigating INVIMA requirements for , as it directly influences their strategic planning and operational decisions in clinical studies. Moreover, it is important to note that the agency is classified as a Level 4 health authority by PAHO/WHO, underscoring its competence and efficiency in health regulation.

    Ensure Post-Approval Compliance and Reporting

    After acquiring regulatory approval, manufacturers must comply with several essential to maintain their registration.

    • : Manufacturers are required to report serious adverse events to the regulatory authority within 72 hours of awareness, while non-serious events must be reported within eight days. This requirement is essential for guaranteeing patient safety and equipment effectiveness, demonstrating the organization’s dedication to overseeing health standards.
    • : Regular updates on the device’s performance, along with any changes in manufacturing processes or labeling, must be submitted to the regulatory authority. This ongoing communication aids in upholding transparency and adherence to regulatory standards, strengthening the organization’s role in supervising the marketing and production of health products.
    • : INVIMA conducts an average of annually to ensure manufacturers comply with . Companies must be prepared for these evaluations to demonstrate their commitment to quality. This is particularly important in light of the significant increase in in Colombia, which rose from 5,447 reports in 2013 to 95,658 in 2017, as highlighted in the case study ‘.’ This increase reflects improved compliance and vigilance in monitoring safety, supported by strategies implemented to enhance the , which is overseen by INVIMA.
    • : Medical equipment registrations are valid for ten years. Manufacturers must submit renewal applications and any updated documentation at least three months prior to the expiration date to avoid lapses in compliance, ensuring that their products continue to meet the stringent standards set by the regulatory body.
    • Adherence to Modifications: Any alterations to the equipment, including changes in design or intended use, must be reported to the regulatory authority for approval prior to implementation. This ensures that all alterations meet regulatory requirements, aligning with INVIMA’s mission to guarantee the safety, efficacy, and quality of . By rigorously adhering to these post-approval obligations, manufacturers can ensure the continued success and safety of their medical devices in the Colombian market while navigating INVIMA requirements for medical devices, in accordance with PAHO/WHO’s classification of INVIMA as a Level 4 health authority.

    This flowchart outlines the essential steps manufacturers must take after regulatory approval to ensure compliance. Follow the arrows from the top to see each requirement and how they connect.

    Conclusion

    Navigating the intricacies of medical device regulation in Colombia is paramount for manufacturers and stakeholders aiming to introduce innovative solutions to the healthcare market. Understanding INVIMA’s multifaceted role is essential, as it not only oversees the approval process but also ensures that devices meet stringent safety and efficacy standards. From the classification of devices to post-market surveillance, INVIMA’s responsibilities shape the landscape of medical technology in Colombia.

    The journey through the INVIMA approval process involves meticulous documentation and a clear understanding of regulatory pathways. By preparing comprehensive registration application dossiers and adhering to INVIMA’s guidelines, stakeholders can facilitate a smoother approval experience. The recent enhancements in the approval timeline reflect a commitment to efficiency, allowing for quicker market entry of essential medical devices.

    Post-approval compliance is equally critical, as manufacturers must engage in ongoing reporting and monitoring to maintain their registrations. Adverse event reporting and regular updates ensure that INVIMA can uphold public health standards while manufacturers demonstrate their commitment to quality and safety. As the medical research sector continues to grow, the importance of compliance with INVIMA’s regulations cannot be overstated.

    Ultimately, the interplay between innovation and regulation in Colombia’s medical device market serves not only to protect public health but also to foster a thriving landscape for medical technology. By understanding and navigating the INVIMA approval process effectively, stakeholders can contribute to addressing the healthcare needs of the Colombian population, ensuring that advancements in medical technology translate into tangible benefits for patients and healthcare providers alike.

    Frequently Asked Questions

    What is the role of INVIMA in Colombia?

    INVIMA is Colombia’s primary regulatory authority for healthcare products, ensuring their safety, effectiveness, and quality before they enter the market.

    What are the key responsibilities of INVIMA?

    INVIMA’s key responsibilities include evaluating clinical data, conducting inspections, and enforcing compliance with national and international regulations.

    How does INVIMA oversee the approval process for medical devices?

    INVIMA supervises the approval process for medical devices by ensuring adherence to established safety and efficacy standards.

    How are medical instruments classified by INVIMA?

    Medical instruments are categorized according to risk levels, which determines the extent of scrutiny during the approval process and establishes the regulatory pathway for each device.

    What is post-market surveillance and why is it important?

    Post-market surveillance involves ongoing oversight of products after approval to ensure continued compliance and safety, highlighting INVIMA’s commitment to public health.

    How many healthcare devices did INVIMA approve in 2025?

    In 2025, INVIMA approved over 150 healthcare devices.

    What growth has the healthcare research sector in Colombia experienced?

    The healthcare research sector in Colombia has experienced over 6% growth in direct employment over the past five years.

    What impact does INVIMA have on healthcare research proposals?

    The success rates for research proposals submitted to INVIMA have risen, indicating its critical role in fostering innovation within the research landscape.

    How can stakeholders prepare for the validation process with INVIMA?

    By understanding INVIMA’s functions, stakeholders can effectively prepare for the subsequent stages in the validation process, facilitating the launch of innovative healthcare devices.

    What role does Bioaccess® play in navigating INVIMA requirements?

    Bioaccess® provides tailored solutions and expertise in regulatory navigation, helping bridge the gap between healthcare needs and new healthcare technologies.

    List of Sources

    1. Understand INVIMA’s Role in Medical Device Regulation
      • meddeviceonline.com (https://meddeviceonline.com/doc/the-large-market-for-medical-devices-in-colombia-may-surprise-you-0001)
      • blog.bioaccessla.com (https://blog.bioaccessla.com/understanding-invima-requirements-for-medtech-clinical-trials-an-in-depth-tutorial)
    2. Gather Essential Documentation for INVIMA Approval
      • blog.bioaccessla.com (https://blog.bioaccessla.com/understanding-invima-requirements-for-medtech-clinical-trials-an-in-depth-tutorial)
      • pureglobal.com (https://pureglobal.com/markets/colombia/invima-medical-device-regulations)
    3. Navigate the INVIMA Approval Process
      • artixio.com (https://artixio.com/post/medical-device-regulations-in-colombia-a-comprehensive-guide)
      • linkedin.com (https://linkedin.com/posts/bioaccess_understanding-the-invima-approval-process-activity-7277735942495301632-9hnL)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC8132005)
    4. Ensure Post-Approval Compliance and Reporting
      • conicalpharmaceuticals.com (https://conicalpharmaceuticals.com/news-events/invima-colombia)
      • researchgate.net (https://researchgate.net/publication/328846854_Report_Of_Adverse_Events_In_Colombia_A_Successful_Case)
      • researchgate.net (https://researchgate.net/publication/336368959_Analysis_of_the_Adverse_Events_and_Incidents_Reported_to_Departmental_Technosurvillance_Program_of_Medical_Devices_in_Antioquia_Colombia_During_2016_and_2017)

  • Argentina And Colombia Just Signed A Regulatory Mou. Here’s What That Means For Medtech Sponsors Running Multi-Country LATAM Trials.

    The Headline

    On June 13, 2026, Argentina’s ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) and Colombia’s INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) signed a Memorandum of Understanding that formalizes bilateral cooperation across medicines, food, and medical devices. The text was published on the INVIMA portal the same day. [INVIMA]

    For sponsors running, planning, or sequencing multi-country clinical programs in Latin America, this matters more than the typical regulatory press release. It is the most operationally consequential change to the Argentina-Colombia regulatory interface since 2018 — and it lands at the exact moment Colombia is finalizing its Decreto Único de Dispositivos Médicos and Argentina is operationalizing ICH E6(R3) Annex 2.

    This article walks through what the MoU actually establishes, what it does not establish, and how MedTech and Biopharma sponsors should sequence their LATAM trials in light of it.

    What The MoU Actually Says

    The June 13 instrument is short on legal flourish and dense on operational substance. Stripped to its four working pillars, the MoU establishes:

    1. Information exchange across regulated categories — covering registration dossiers, surveillance signals, and inspection findings.
    2. Protocol and best-practices sharing — methodologies, technical guidance, and procedural alignment on common review pathways.
    3. Joint project collaboration — coordinated capacity-building initiatives, training exchanges, and technical mission programming.
    4. Confidentiality and monitoring framework — formal governance of how shared data is handled and how cooperative activities are tracked over time.

    The cooperation explicitly covers medicines, food, and medical devices. That last category is the one many sponsors miss. The 2014 and 2018 instruments between the two agencies were narrower — 2014 focused on “exchange of experiences and good practices,” and 2018 was specifically about Good Manufacturing Practice inspection records. The 2026 MoU is the first comprehensive framework that unifies the medical device dimension with pharmaceuticals and food under a single working architecture. [ANMAT Cooperation Registry]

    What The MoU Does Not Do

    Three clarifications worth front-loading, because we are already seeing them misunderstood in early secondary commentary.

    The MoU does not create single-window approvals. A sponsor preparing a clinical trial in both Argentina and Colombia still files two separate dossiers, with two separate regulatory teams, on two distinct timelines. ANMAT continues to operate Disposición 7516/25 and the Resolution 1480/2011 ethics framework. INVIMA continues to operate under Decreto 4725 de 2005 and Resolución 1229 de 2013 until the new Decreto Único is published.

    The MoU does not formalize automatic reliance. Reliance — where one regulator can lean on another’s scientific assessment to shorten its own review — exists as a regulatory principle in both agencies’ modernization agendas, but the MoU itself does not create a reliance pathway between them. It creates the plumbing through which such pathways can later be built.

    The MoU does not change cost or fee structures. Sponsors should not expect this instrument to reduce regulatory review fees, ethics committee charges, or local sponsor representation costs in either jurisdiction.

    What It Does, In Practice

    What the MoU does, immediately, is formalize four operational improvements that previously depended on ad-hoc coordination through ICH Assembly hallway conversations and the International Pharmaceutical Regulators Programme (IPRP) plenary sessions.

    One. When a sponsor’s submission triggers a safety signal in one country, that signal can now flow through a structured channel to the other regulator within a defined confidentiality envelope. Before this MoU, a sponsor with a flagged adverse event in Argentina would typically receive an independent inquiry from Colombia weeks or months later, often duplicating the original investigation. After this MoU, the two regulators can coordinate the inquiry’s timing and scope.

    Two. Inspection of a sponsor or manufacturer operating in both jurisdictions can be coordinated. A single inspection mission, with two regulators present or with shared inspection reporting, materially compresses the sponsor’s compliance overhead.

    Three. Capacity-building and training activities — pharmacovigilance, tecnovigilancia, quality risk management — can be conducted jointly. This raises the technical floor in both countries, which is good for sponsors because the predictable downside of trial expansion to a smaller-budget regulator is technical inconsistency at the review level.

    Four. Standards and review methodologies can be aligned over time. The MoU does not specify which standards or methodologies, but it creates the working group structure to negotiate them. The most likely early candidates are software-as-a-medical-device classification, AI/ML model change pathways, and harmonization of IMDRF-aligned UDI requirements.

    The Decreto Único Context

    The MoU lands during one of the most active periods of Colombian medical device regulatory reform in two decades. Colombia’s Decreto Único de Dispositivos Médicos — a 16-chapter, 180-article instrument that consolidates and replaces Decretos 4725/2005 and 3770/2004 — completed its national public consultation phase and entered WTO international consultation on May 18, 2026. The comment window closes July 17, 2026. [CONSULTORSALUD]

    INVIMA’s Director of Medical Devices and Other Technologies, Doris Yolima Gómez Parada, has been publicly explicit about the substantive direction: indefinite-validity authorizations (conditioned on post-market performance), strengthened tecnovigilancia, mandatory Unique Device Identification (UDI) at initial registration, IMDRF-aligned risk classification (three classes expanding to four), and an explicit reliance framework that recognizes FDA, EMA, and ANVISA assessments — supplemented by Pacific Alliance, Rio Accord, and WHO Listed Authority qualifications.

    For a multi-country sponsor, the implication is direct: the Decreto Único modernizes Colombia’s regulatory architecture in ways that are structurally compatible with Argentina’s ICH E6(R3) Annex 2 adoption. The June 13 MoU is the procedural connective tissue between the two modernizations.

    The Argentina Side: ICH Annex 2 Operative

    Argentina entered this MoU from a position of unusual regulatory strength. ANMAT adopted the ICH E6(R3) operative framework under Disposición 7516/25, and Annex 2 — the risk-proportionate quality management addendum — was finalized to Step 4 at the ICH Assembly in Rio de Janeiro on June 3, 2026, two weeks before the MoU was signed. ANMAT confirmed participation in both the ICH Assembly and the IPRP sessions of June 3-4.

    Argentina’s documented FIH timeline benchmark currently sits at 62 days from study start to first patient enrolled, inclusive of ethics committee review, ANMAT regulatory authorization, and clinical site activation. That benchmark assumes a well-prepared sponsor working with operational sites in greater Buenos Aires, La Plata, Mendoza, and Rosario.

    The MoU’s value to an Argentina-primary sponsor is that secondary expansion into Colombia — historically a separate operational track with limited information continuity — now sits on a coordinated information channel. The Decreto Único’s reliance pathway, once operational, can in principle leverage Argentina-generated dossier work for parts of the Colombian submission.

    Practical Implications: How To Sequence A Multi-Country Trial Now

    For a MedTech, Biopharma, or Radiopharma sponsor planning a 2026-2027 LATAM trial, the operational sequencing question changes in three ways.

    Argentina-primary sequencing is now operationally cleaner. If your indication has equivalent patient availability in both Argentina and Colombia, starting in Argentina has three compounding advantages: ICH E6(R3) Annex 2 inspection-readiness, a 62-day study start timeline, and — under the MoU — a smoother information bridge into Colombia for the secondary expansion.

    Colombia is no longer a second-tier choice for sponsors with cardiovascular, oncology, or rare-disease indications. The combination of the MoU plus the Decreto Único’s reliance framework plus Colombia’s IMDRF affiliate member status (effective September 2025) materially raises Colombia’s strategic value. The five-month Colombian FIH timeline that has been the benchmark for the past three years will compress meaningfully once the Decreto Único is in force.

    The IRB and ethics committee dimension matters more, not less. The MoU does not touch independent ethics committee review. Sponsors gain little if their Argentine site is approved in 62 days and the Colombian ethics committee for a comparable indication takes four months. Operational selection of ethics committees with proven turnaround for the relevant therapeutic area becomes a larger fraction of the timeline gap.

    What To Watch Between Now And September

    Four watch items will determine how much of the MoU’s potential operational value crystallizes in 2026.

    July 17: The WTO comment window on the Decreto Único closes. Industry comment density and the substance of the final text will shape whether reliance is operationally meaningful or a paper provision.

    Late Q3 2026: Implementing language for the MoU. The instrument as signed is a framework. Working-group structure, the first joint technical projects, and any joint training program will signal how seriously both agencies intend to execute on the framework.

    Q4 2026: Decreto Único publication. The 18-month transition period for industry begins on publication. Sponsors should plan for a 2027 implementation horizon for the new Colombian regime.

    2027 onward: First coordinated inspection. If ANMAT and INVIMA execute a coordinated inspection of a sponsor or manufacturer operating in both countries, that becomes the case study that defines the MoU’s operational reality.

    Why This Matters For Operating At Scale In LATAM

    We have been operating multi-country clinical programs in Latin America since 2010. Across 47 first-in-human studies for MedTech, Biopharma, and Radiopharma sponsors, the practical bottleneck in expanding from a single-country trial to a regional program has rarely been regulatory text. It has been the discontinuities between regulators — different document formats, divergent timing assumptions, ethics committees that interpret international guidance differently, and the absence of any structured channel for coordinating safety information when a study runs in parallel in two jurisdictions.

    The MoU is the first instrument in our operating memory that addresses those discontinuities directly. It does not eliminate them. It builds the architecture inside which they can be addressed deliberately, instead of through ad-hoc coordination at ICH meetings.

    For sponsors evaluating LATAM right now, the immediate practical advice is: do not wait. The MoU’s value compounds for sponsors who establish operational presence in both Argentina and Colombia before the implementing language is in place — because those sponsors will be the test cases that shape how the MoU actually works. By the time the framework is mature, the operational advantage will have moved downstream.

    The Bottom Line

    The Argentina-Colombia MoU of June 13, 2026, does not change clinical trial regulation in either country. It changes the operating architecture between them. For multi-country LATAM sponsors, that architecture is the part of the regulatory environment that has been hardest to manage, and it is the part that has been most resistant to structural improvement.

    If your 2026-2027 strategic plan included evaluating LATAM as a multi-country option for an FIH or early-feasibility study, the case just got materially stronger. If your plan did not include LATAM, the regulatory ceiling that previously made multi-country expansion operationally difficult has been formally lifted.

    The two LATAM regulators with the deepest reform agendas in the region just connected their working architecture. The sponsors who move first will define what the connection means.

    bioaccess® is a clinical research organization purpose-built for first-in-human and early-phase studies for MedTech, Biopharma, and Radiopharma startups in Latin America. We have supported 47 FIH programs since 2010 across Argentina, Brazil, Colombia, Mexico, Costa Rica, and Panama. To discuss a multi-country LATAM trial strategy, contact us at info@bioaccessla.com or visit bioaccessla.com/roadmap.

  • How to Book an Expert Teleconference with INVIMA Successfully

    How to Book an Expert Teleconference with INVIMA Successfully

    Introduction

    Navigating the complexities of regulatory agencies can be daunting, particularly when scheduling crucial teleconferences with organizations like INVIMA. It’s essential to understand the necessary documentation and specific requirements to ensure a smooth and productive meeting. Many individuals grapple with the intricacies of the booking process, which often leads to frustration and delays.

    So, how can one effectively prepare and troubleshoot common issues to secure a successful teleconference with INVIMA? This article will explore these challenges and provide actionable insights to enhance your experience.

    Gather Necessary Documentation and Information

    To effectively arrange a remote meeting with the agency, it’s crucial to gather all and information. This preparation not only streamlines the process but also ensures compliance with regulatory standards. Here’s what you need:

    1. Application Form: Complete the agency’s , which can be found on their official website.
    2. : Assemble a detailed that includes product specifications, safety data, and relevant certifications.
    3. : Gather that prove , such as prior approvals or .
    4. Contact Information: Ensure that accurate contact details for all participants in the virtual meeting are readily available.
    5. : Create a clear agenda that outlines the topics to be discussed during the virtual meeting.

    Having these documents prepared will not only simplify the but also assist in meeting regulatory requirements, ultimately leading to a more efficient online meeting experience.

    Each box represents a step you need to take to prepare for your remote meeting. Follow the arrows to see the order in which you should gather your documents.

    Understand INVIMA’s Requirements for Teleconferences

    Before scheduling a teleconference with INVIMA, it’s crucial to grasp their specific requirements:

    1. : Confirm that your inquiry or submission qualifies for a teleconference. The agency prioritizes discussions related to or urgent inquiries during the book expert teleconference invima, ensuring that only relevant matters are addressed.
    2. : Familiarize yourself with the established by INVIMA. This may include specific formats or additional information that must be included in your submission to facilitate a productive discussion.
    3. Timeframes: Be aware of the typical for . The regulatory agency may have specified times for availability, which can influence your planning.
    4. : Check if there are limitations on the number of attendees permitted in the virtual meeting. Understanding these limits is crucial for and communication.
    5. : Ensure that you are familiar with the technical specifications of the virtual meeting platform utilized by the organization. This includes checking connectivity options and ensuring that all participants can join without technical difficulties.

    By thoroughly understanding these requirements, you can effectively customize your approach to meet the organization’s expectations and enhance the likelihood of a .

    The central node represents the main topic, while each branch shows a specific requirement. Follow the branches to see what you need to know for a successful teleconference with INVIMA.

    Schedule the Teleconference with INVIMA

    To successfully schedule your teleconference with , follow these streamlined steps:

    1. : Visit the official website and navigate to the section for arranging online conferences.
    2. : Complete the online scheduling form with precision, providing essential details such as your contact information, the purpose of the , and your preferred dates and times.
    3. : Upload any necessary documentation that supports your request, including the technical dossier and agenda, to ensure a thorough submission.
    4. : Review all entered information carefully for accuracy before submitting your meeting request.
    5. Confirmation: Await validation from the regulatory authority regarding the scheduled date and time of your video conference. They may provide additional instructions or requirements at this stage.

    Statistics reveal that 71% of managers find meetings unproductive, underscoring the in planning processes. As Simon Sinek aptly noted, “,” emphasizing the critical role of effective communication in achieving successful outcomes. By adhering to these steps, you can with the book expert teleconference organization.

    Each box represents a step in the process of scheduling your teleconference. Follow the arrows to see how to move from one step to the next, ensuring you complete each part before proceeding.

    Troubleshoot Common Issues During the Booking Process

    When arranging a teleconference with the organization, you may encounter several . Here’s how to effectively troubleshoot them:

    1. : If you experience problems with the portal, begin by clearing your browser cache or switching to another browser. A stable internet connection is crucial for a smooth experience.
    2. : Ensure that all required documents are formatted correctly and complete. Incomplete or incorrect submissions can lead to significant delays in the .
    3. : If you do not receive a confirmation within the expected timeframe, promptly follow up with the relevant authority via email or phone to verify that your request was received.
    4. : Should your preferred time be unavailable, remain flexible with alternative dates and times. Utilizing a can help identify common availability among all participants.
    5. : In cases of language barriers or misunderstandings, consider hiring a translator or using clear, concise language in your communications to avoid confusion.

    By proactively addressing these common issues, you can significantly improve your chances of successfully booking a teleconference with INVIMA.

    Each box represents a common issue you might face when booking a teleconference. Follow the arrows to see the recommended steps to resolve each problem.

    Conclusion

    Successfully booking a teleconference with INVIMA requires meticulous preparation and a clear understanding of the agency’s requirements. By following the outlined steps, individuals can streamline the process, ensuring that all necessary documentation is in order and that the meeting is scheduled efficiently.

    Key points discussed include the importance of gathering essential documents such as the application form, technical dossier, and regulatory documents. Understanding INVIMA’s specific requirements, including eligibility criteria and participant limits, is crucial for a productive meeting. Moreover, troubleshooting common issues like technical difficulties and documentation errors can significantly enhance the likelihood of success in scheduling the teleconference.

    In conclusion, taking the time to prepare thoroughly not only facilitates a smoother booking process but also sets the stage for a more effective and insightful discussion with INVIMA. Engaging with regulatory agencies like INVIMA can be complex, yet with the right approach and adherence to best practices, it becomes a manageable and rewarding experience. Embrace these guidelines to ensure that your next teleconference is not just a meeting, but a strategic step toward achieving your regulatory goals.

    Frequently Asked Questions

    What is the first step to arrange a remote meeting with the agency?

    The first step is to gather all necessary documentation and information to streamline the process and ensure compliance with regulatory standards.

    What documentation is required to arrange a remote meeting?

    Required documentation includes a completed video conference application form, a detailed technical dossier, regulatory documents, accurate contact information for participants, and a clear meeting agenda.

    Where can I find the video conference application form?

    The video conference application form can be found on the agency’s official website.

    What should be included in the technical dossier?

    The technical dossier should include product specifications, safety data, and relevant certifications.

    What are regulatory documents, and why are they needed?

    Regulatory documents are those that prove compliance with INVIMA’s requirements, such as prior approvals or clinical trial protocols, and they are needed to ensure that all regulatory standards are met.

    Why is it important to have accurate contact information for all participants?

    Having accurate contact information is crucial to ensure effective communication and coordination among all participants in the virtual meeting.

    What is the purpose of creating a meeting agenda?

    The meeting agenda serves to outline the topics to be discussed during the virtual meeting, helping to keep the discussion organized and focused.

    List of Sources

    1. Gather Necessary Documentation and Information
      • azquotes.com (https://azquotes.com/quotes/topics/documentation.html)
      • How to Navigate the INVIMA Clinical Trial Submission Process: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/how-to-navigate-the-invima-clinical-trial-submission-process-a-step-by-step-guide)
      • pureglobal.com (https://pureglobal.com/markets/colombia/invima-medical-device-regulations)
      • Understanding INVIMA Clinical Trial Requirements: An In-Depth Tutorial | bioaccess® (https://bioaccessla.com/blog/understanding-invima-clinical-trial-requirements-an-in-depth-tutorial)
    2. Understand INVIMA’s Requirements for Teleconferences
      • pureglobal.com (https://pureglobal.com/news/colombia-invima-2026-guidance-clarifies-udi-di-requirements-for-class-iia-medical-devices)
      • gpcgateway.com (https://gpcgateway.com/news/detail/invima-announces-no-registration-required-for-conventional-and-daily-use-toothbrushes-in-colombia/MjMxMw==)
      • Understanding INVIMA Clinical Trial Requirements: An In-Depth Tutorial | bioaccess® (https://bioaccessla.com/blog/understanding-invima-clinical-trial-requirements-an-in-depth-tutorial)
      • infoalimentario.com (https://infoalimentario.com/2026/02/02/colombia-invima-will-update-fees-for-food-related-procedures-in-2026)
    3. Schedule the Teleconference with INVIMA
      • 85 quotes about communication in business to motivate teams and leaders (https://textline.com/blog/quotes-about-communication-in-business)
      • vibe.us (https://vibe.us/blog/35-quotes-about-communication?srsltid=AfmBOop5Gs-BRAx8zhO875E6YcGDLHuZoHl-qhncYFaib9G55Wd4Zl66)
      • 21 Motivational Communication Quotes for Work (https://niagarainstitute.com/blog/communication-quotes)
      • 36 Workplace Communication Quotes to Inspire Your Team (https://trinet.com/insights/workplace-communication-quotes)
      • notta.ai (https://notta.ai/en/blog/meeting-statistics)
    4. Troubleshoot Common Issues During the Booking Process
      • pharmaregulatory.in (https://pharmaregulatory.in/common-pitfalls-in-regulatory-submissions-to-invima-pharma-gxp)
      • raps.org (https://raps.org/News-and-Articles/News-Articles/2024/1/Latin-America-Roundup-Colombia’s-INVIMA-faces-crit)

  • 4 Steps for Effective Pre-Submission Teleconference INVIMA Planning

    4 Steps for Effective Pre-Submission Teleconference INVIMA Planning

    Introduction

    Understanding the intricate landscape of regulatory submissions is essential for any organization aiming to navigate the complexities of medical device and pharmaceutical approvals in Colombia. The National Food and Drug Surveillance Institute (INVIMA) plays a crucial role in this process. Effective pre-submission teleconference planning can significantly enhance the chances of a successful application. However, many organizations face challenges in aligning their objectives with INVIMA’s expectations. This leads to a critical question: what are the key steps to ensure a productive teleconference that not only meets regulatory requirements but also fosters clear communication and effective follow-up?

    Understand INVIMA’s Role in Regulatory Submissions

    The plays a pivotal role in the , pharmaceuticals, and . Understanding its functions is essential for effective . This regulatory body oversees the , ensuring that all applications adhere to stringent safety, efficacy, and quality standards.

    Familiarizing yourself with the organization’s guidelines—including the , timelines, and necessary documentation—will significantly enhance your preparedness for the . This crucial knowledge aligns your objectives with the agency’s expectations, thereby increasing the likelihood of successful regulatory filings.

    As of 2025, the has been optimized, with within just 4 to 6 weeks, and the overall timeline for medical device registration typically spanning 2 to 4 months. Grasping these dynamics is vital for effectively navigating the complexities of the .

    Each box represents a step in the process of preparing for and submitting applications to INVIMA. Follow the arrows to understand the sequence of actions, and check the sub-boxes for timeline expectations.

    Prepare Key Documentation and Questions for the Teleconference

    Thorough planning for the pre-submission teleconference is essential for a successful application process. Begin by gathering all essential documentation, which includes:

    In addition to the documentation, it is vital to formulate or uncertainties regarding the . Organize these questions by topic to facilitate a structured discussion. For instance, consider inquiring about:

    • Recent changes in ‘s policies

    Having this information readily available will enable you to engage effectively during the meeting, ensuring that all critical aspects of your submission are addressed.

    The center node is your main theme, and the branches show the key documentation and questions that will help you prepare for the teleconference. Follow the branches to see what information you need to gather and what topics to discuss.

    Develop Effective Communication Strategies for the Meeting

    To enhance communication during the teleconference, it is imperative to implement the following strategies:

    • Set a : Distributing a well-defined agenda prior to the meeting is crucial. This should outline the topics to be discussed and allocate specific time slots for each item. Research indicates that only , underscoring the necessity for organized discussions. A serves as a roadmap, ensuring conversations remain focused and relevant. In fact, .
    • : Creating an inclusive environment is essential for . Actively inviting all participants to share their insights and questions, particularly encouraging quieter members to contribute, fosters collaboration and enhances the overall quality of the discussion.
    • Use : Incorporating , such as slides or documents, can significantly enhance understanding. Visuals elucidate intricate information and , which is vital in a virtual meeting environment where focus can easily wane.
    • : At the conclusion of each topic, and outlining any decisions made is vital. This practice ensures that all participants are aligned and informed about the next steps, reducing the likelihood of misunderstandings and enhancing the discussion’s effectiveness.

    By concentrating on these strategies, organizations can elevate their virtual meeting outcomes with regulatory bodies through , ensuring that discussions are productive and aligned with their objectives.

    The center shows the main focus on communication strategies, and the branches represent each specific strategy. Follow the branches to see how each strategy contributes to effective communication.

    Implement Follow-Up Actions Post-Teleconference

    To ensure effective follow-up after the teleconference with INVIMA, consider the following actions:

    • Send a Summary Email: that captures key points discussed, decisions made, and action items assigned to specific individuals. This not only reinforces understanding but also serves as a reference for all participants.
    • Schedule Next Steps: Promptly organize any required follow-up discussions or . Clearly outline deadlines for tasks assigned during the teleconference to ensure accountability.
    • Monitor Progress: Regularly check in with team members regarding their assigned tasks. This can be achieved through brief updates or follow-up discussions, ensuring that everyone remains on track and any potential issues are addressed quickly.

    through by sending any additional questions or clarifications that arise post-meeting. This proactive approach demonstrates your commitment to compliance and fosters a collaborative relationship.

    Statistics indicate that significantly enhance the , with . Therefore, implementing these follow-up strategies is crucial for maintaining a competitive edge in the .

    Each box represents a critical follow-up action to take after the teleconference. Follow the arrows to see the order in which these actions should be completed for effective communication and task management.

    Conclusion

    Effective pre-submission teleconference planning with INVIMA is crucial for navigating the complexities of regulatory submissions in Colombia. Understanding INVIMA’s role, preparing key documentation, developing effective communication strategies, and implementing follow-up actions significantly enhance the chances of a successful application process. This structured approach aligns objectives with regulatory expectations and fosters a collaborative relationship with INVIMA.

    The article highlights essential steps, including:

    1. Familiarizing oneself with INVIMA’s guidelines
    2. Gathering necessary documents
    3. Crafting specific questions to ensure clarity during discussions

    Furthermore, it emphasizes the importance of:

    • A clear agenda
    • Participant engagement
    • The use of visual aids to facilitate effective communication

    Following the teleconference, timely follow-up actions, such as sending summary emails and monitoring progress, are vital for maintaining momentum and accountability.

    In summary, thorough preparation and strategic communication are paramount for successful interactions with INVIMA. By adopting these best practices, stakeholders can navigate the regulatory landscape more effectively, ensuring compliance and fostering positive relationships with regulatory bodies. Embracing these insights will streamline the submission process and position organizations for long-term success in the pharmaceutical and medical device sectors.

    Frequently Asked Questions

    What is the role of INVIMA in Colombia?

    INVIMA, the National Food and Drug Surveillance Institute in Colombia, regulates medical devices, pharmaceuticals, and clinical trials, overseeing the approval process to ensure compliance with safety, efficacy, and quality standards.

    Why is it important to understand INVIMA’s functions before a submission?

    Understanding INVIMA’s functions is essential for effective pre-submission teleconference planning, as it helps align your objectives with the agency’s expectations, increasing the likelihood of successful regulatory filings.

    What should applicants familiarize themselves with when preparing for INVIMA submissions?

    Applicants should familiarize themselves with INVIMA’s guidelines, including the types of applications required, timelines, and necessary documentation to enhance their preparedness for the submission process.

    What is the typical timeline for medical device registration in Colombia as of 2025?

    As of 2025, the overall timeline for medical device registration typically spans 2 to 4 months, with ethical approvals attainable within 4 to 6 weeks.

    How can understanding the regulatory timeline help applicants?

    Grasping the regulatory timeline helps applicants effectively navigate the complexities of the Colombian regulatory landscape, allowing for better planning and management of their submissions.

    List of Sources

    1. Understand INVIMA’s Role in Regulatory Submissions
      • iaocr.com (https://iaocr.com/colombias-regulatory-authority-for-clinical-trials)
      • Understanding INVIMA Requirements for Medtech Clinical Trials: An In-Depth Tutorial | bioaccess® (https://bioaccessla.com/blog/understanding-invima-requirements-for-medtech-clinical-trials-an-in-depth-tutorial)
      • bioaccessla.com (https://bioaccessla.com/es/blog/10-essential-insights-on-invima-risk-classification-guide)
    2. Prepare Key Documentation and Questions for the Teleconference
      • How to Navigate the INVIMA Clinical Trial Submission Process: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/how-to-navigate-the-invima-clinical-trial-submission-process-a-step-by-step-guide)
      • Understanding INVIMA Clinical Trial Requirements: An In-Depth Tutorial | bioaccess® (https://bioaccessla.com/blog/understanding-invima-clinical-trial-requirements-an-in-depth-tutorial)
      • blog.medpoint.com (https://blog.medpoint.com/6-best-practices-in-regulatory-writing)
      • asphalion.com (https://asphalion.com/key-considerations-and-tips-for-submitting-good-submission-files-to-regulatory-authorities)
    3. Develop Effective Communication Strategies for the Meeting
      • aiscreen.io (https://aiscreen.io/digital-signage-employee-communications/statistics-about-employee-communications)
      • flowtrace.co (https://flowtrace.co/collaboration-blog/50-meeting-statistics)
      • 43 Remarkable Workplace Communication Statistics in 2026 (https://apollotechnical.com/workplace-communication-statistics)
      • Business Communication Statistics 2026 | Project.co (https://project.co/communication-statistics)
      • Workplace Communication Statistics for 2026 (https://pumble.com/learn/communication/communication-statistics)
    4. Implement Follow-Up Actions Post-Teleconference
      • profitoutreach.app (https://profitoutreach.app/blog/sales-follow-up-statistics)
      • 130+ Compliance Statistics & Trends to Know for 2026 (https://secureframe.com/blog/compliance-statistics)
      • mtdsalestraining.com (https://mtdsalestraining.com/mtdblog/sales-follow-up-statistics.html)
      • qwilr.com (https://qwilr.com/blog/sales-follow-up-statistics)
      • These Numbers Will Show You Why Sending Follow-up Emails Is Crucial (https://woodpecker.co/blog/follow-up-statistics)